New England Journal of Medicine· 2017Q1

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, Xavier Leleu et al.

1,238citations
Q1SCImago
2017year

Short summary

High-dose chemotherapy plus stem-cell transplantation combined with lenalidomide, bortezomib, and dexamethasone (RVD) therapy resulted in significantly longer progression-free survival (50 months vs. 36 months) compared to RVD therapy alone in newly diagnosed multiple myeloma patients.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine